Verily adds to its clinical trials toolbox with acquisition of startup SignalPath
Verily’s recent moves have signaled the company’s interest in supporting decentralized clinical trials and real-world studies. Now the life sciences subsidiary of Alphabet is bolstering its capabilities in these areas with the acquisition of startup SignalPath.